Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.

[1]  Y. Choi,et al.  Zoonotic infections with avian influenza A viruses and vaccine preparedness: a game of "mix and match" , 2014, Clinical and experimental vaccine research.

[2]  D. Skowronski,et al.  Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses , 2014, PloS one.

[3]  Tom Jefferson,et al.  Vaccines for preventing influenza in healthy adults. , 2014, The Cochrane database of systematic reviews.

[4]  J. Noh,et al.  Long‐term and cross‐reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59‐adjuvanted vaccine versus unadjuvanted vaccine , 2013, Journal of medical virology.

[5]  P. Tambyah,et al.  Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine , 2012, Expert review of vaccines.

[6]  H. Ikematsu,et al.  Evaluation of Influenza Virus A/H3N2 and B Vaccines on the Basis of Cross-Reactivity of Postvaccination Human Serum Antibodies against Influenza Viruses A/H3N2 and B Isolated in MDCK Cells and Embryonated Hen Eggs , 2012, Clinical and Vaccine Immunology.

[7]  T. Vesikari,et al.  Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Itai Ashlagi,et al.  Mix and match , 2010, EC '10.

[9]  W. Choi,et al.  Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. , 2010, Vaccine.

[10]  W. Choi,et al.  [The evaluation of policies on 2009 influenza pandemic in Korea]. , 2010, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[11]  K. Reisinger,et al.  Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. , 2009, The Journal of infectious diseases.

[12]  S. Halperin,et al.  Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines) , 2009, Expert review of vaccines.

[13]  J. Gregersen.  A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine , 2008, Vaccine.

[14]  H. Cheong,et al.  Debate on annual influenza vaccination in healthcare workers for the same subtype under the vaccine shortage. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .